• Astrazeneca Pharma Receives DCGI Approval For Launch Diabetes Drug In India

    • September 27, 2019
    • Posted By : admin
    • 0 Comment
    •   36 views

    Astrazeneca Pharma India has received Import and Market permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets.

    The receipt of this Import and Market permission paves way for the launch of FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN) in India, subject to the receipt of other related statutory approvals and licenses.

    FDC of Dapagliflozin 10mg + Saxagliptin 5mg is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM).

  36 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!